Vasundhara Rasy. (538634)
TurnaroundScore breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1
Key Financials
| Current Price | ₹279.85 |
| Market Cap | ₹90.11 Cr |
| P/E Ratio | 10.79 |
| ROCE | 16.56% |
| ROE | 10.26% |
| Dividend Yield | 1.55% |
| Profit Growth | -50.34% |
| Debt/Equity | — |
| Sales Growth | -15.53% |
| 52-Week Range | ₹100.1 — ₹279.85 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹125.24 |
Strengths
- ROCE of 16.56% suggests decent operational capital efficiency despite the small scale.
- Book value of ₹125.24 provides some asset backing; P/B of 2.23 is not excessive.
- P/E of 10.79 and dividend yield of 1.55% offer some cushion if earnings stabilise.
- Latest quarter is still profitable: ₹1 Cr net profit on ₹7 Cr sales.
Concerns
- Sales down 15.53% and profit down 50.34% show clear fundamental deterioration.
- Piotroski F-Score of 3/9 signals weak financial health.
- Stock trades at its 52-week high of ₹279.85 despite declining earnings; market may be ahead of fundamentals.
- Debt/equity and promoter holding are not disclosed, leaving important transparency gaps.
AI Analysis
At today's price of ₹279.85, Vasundhara Rasy carries a market cap of just ₹90 Cr. On the surface, a P/E of 10.79 and a dividend yield of 1.55% look reasonable, but Graham would ask: is the earnings power real and durable? The answer is not reassuring. Trailing profits have fallen 50.34% and sales are down 15.53%; the latest quarter shows only ₹7 Cr in revenue and ₹1 Cr in profit. If that run-rate annualises, the effective P/E is far higher than the advertised 10.79. The Piotroski F-Score of 3/9 reinforces my caution. This is a business with deteriorating fundamentals, not a quietly compounding franchise. I do like that ROCE is 16.56% and book value is ₹125.24, so the stock is not trading at an absurd premium. But the price has already risen from a 52-week low of ₹100.10 to a high of ₹279.85. The market is pricing in a recovery that the numbers have not yet shown. Buffett says it is wonderful to buy a great company at a fair price; here I do not yet know if the business is great, or merely small and struggling. Without promoter holding data and with a weak F-score, the margin of safety is thin. I would not chase this rally. I would put Vasundhara Rasy on a watch list and wait for evidence of stabilisation: higher sales, stable margins, and restored profitability. Until then, this is a possible turnaround, not an established compounder.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer